1Abate N, Vega GL, Garg A, et al. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis, 1995,118(1):111 - 122.
2Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator- activated receptor (PPAR)in mediation the effects of fibratesand fatty acids on gene expression. J Lipid Res, 1996,37:907 - 925.
3Kamanna VS, Bassa BV, Kirschenbaum MA. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Curr Opin Nephrol Hypertens,1997,6(3) :205 - 211.
4Gyone EF, Walli AK, Gyone HJ, et al. The role of lipids in nephrosis and glomerulosclerosis. Atherosclerosis, 1994, 107(1):1-13.
5Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest, 1997,100(12) :2995 - 3004.
6Soedamah-Muthu SS, Colhoun HM, Taskinen MR,et al.Differences in HDL - cholesterol: apoA - Ⅰ + apoA - Ⅱratio and apoE phenotype with albuminuric status in Type Ⅰ diabetic patients. Diabetologia,2000, 43 (11): 1353 -1359.
7Hirano T, Oi K, Sakai S, et al. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia.Atherosclerosis, 1998,141 (1): 77 - 85.
8Hirano T, Naito H, Kurokawa M, et al. High prevalence of small LDL particles in non - insulin - dependent diabetic patients with nephropathy. Atherosclerosis, 1996, 123( 1 -2):57.
9Wheeler DC, Chana RS, Topley N,et al. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int, 1994,45(6): 1628 - 1636.
10Amanna VS, Bassa BV, Kirschenbaum MA. Atherogenic lipoproteins and human disease: extending concepts beyond the heart to the kidney. Curr Opin Nephrol Hypertens,1997,6(3) :205 - 211.
6Hagiwara S, Makita Y, Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP- 1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant, 2006,21 (3) : 605 - 615.
7Feiten SF, Draibe SA, Watanabe R, et al. Short - term effects of a very- low- protein diet supplemented with ketoacids in nondialyzed chronic kidney disease patients. Eur J Clin Nutr, 2005, 59(1 ) : 129 - 136.
8Eyre S,Attman PO, Haraldsson B. Positive effects of protein restriction in patients with chronic kidney disease. J Ren Nutr, 2008,18(3) :269 - 280.
9Nishitani S, Ijichi C, Takehana K, et al. Pharmacoloical activities of branchedchain amino acid: specificity of tissue and signal transduction. Biochem Biophys Res Commun, 2004,313 (2) : 387 - 389.
10Teplan V, Schuck O, Votruba M, et al. Metabolic effects of keto acid - amino acid supplementation in patients with chronic renal insufficiency receiving a low - protein diet and recombinant human erythropoietin - a randomized controlled trail. Wien Klin Wochenschr,2001,113( 17 - 18) :661 - 669.
